Diabetes e hipertensión
Tratamiento y manejo
Revisado por Dr Toni Hazell, FRCGPÚltima actualización por Dr Philippa Vincent, MRCGPÚltima actualización 1 Oct 2026
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Versión en audio
- Agregar a fuentes preferidas en Google
Profesionales Médicos
Los artículos de Referencia Profesional están diseñados para ser utilizados por profesionales de la salud. Están escritos por médicos del Reino Unido y se basan en evidencia de investigación, así como en guías del Reino Unido y Europa. Puede encontrar el Diabetes e hipertensión arterial artículo más útil, o uno de nuestros otros artículos de salud.
This article aims to provide a simple management plan for the management of people with diabetes mellitus who also have raised blood pressure (BP). It is based mainly on the current National Institute for Health and Care Excellence (NICE) recommendations. See also the Hipertensión y Tratamiento de la hipertensión artículos.
Patients with type 2 diabetes mellitus have a significantly higher risk of cardiovascular morbidity and mortality and are disproportionately affected by cardiovascular disease.123 Most of this excess risk is associated with high prevalence of well-established risk factors such as hypertension, dyslipidaemia, and obesity in these patients.4 Hypertension plays a major role in the development and progression of microvascular and macrovascular disease in people with diabetes.1
Early intervention and targeting multiple risk factors with both lifestyle and pharmacological strategies give the best chance of reducing macrovascular complications in the long term.5
Thiazides and beta-blockers, whilst effective for blood pressure reduction, can cause increased insulin resistance making them less beneficial in diabetes. ACE inhibitors, and ARBs are cardio-protective and renally protective in diabetes and should be used for hypertension management.6
Epidemiología
Hypertension is more prevalent in patients with type 2 diabetes than in those who don't have diabetes.4
Hypertension occurs more commonly in patients with type 2 diabetes, with estimates of between 50 and 80%, whilst type 2 diabetes also occurs 2.5 times more often in patients with hypertension than those without.7
Adults who have both diabetes and hypertension have more kidney disease and atherogenic risk factors including dyslipidaemia, hyperuricaemia, elevated fibrinogen, and left ventricular hypertrophy.
Midiendo la presión arterial8
Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.
Measure standing as well as seated blood pressure. In people with a significant postural drop or symptoms of postural hypotension, treat to a blood pressure target based on standing blood pressure.
Provide lifestyle advice (diet and exercise) at the same time. See also the separate Dieta y ejercicio para la diabetes artículo.
Manejo8
NICE recommends a blood pressure target of below 140/90 mm Hg for adults with type 1 diabetes and an albumin creatinine ratio of less than 70. If they have an ACR of more than 70, NICE recommends a blood pressure target of below 130/80 mm Hg. In adults with type 2 diabetes, the target remains below 140/90.
In adults over 80 with diabetes, the BP target is below 150/90.
American targets are lower than European targets, recommending blood pressure of below 130/80 mm Hg in all patients with diabetes.9
There is good evidence that reducing BP to these levels improves cardiovascular outcomes but there is also evidence that reducing blood pressure to less than 120/70 may increase adverse events.1011
Reduce other risks of cardiovascular disease and other complications of diabetes - eg, smoking cessation, weight reduction, improvement of glycaemic control, and management of hyperlipidaemia.12
Tratamiento farmacológico8
Offer an ACE inhibitor or an angiotensin-2 receptor blocker (ARB) to adults starting step 1 antihypertensive treatment who have type 2 diabetes. (NB: for adults of black African or African-Caribbean family origin, consider an ARB in preference to an ACE inhibitor.) If an ACE inhibitor causes side effects, an ARB should be offered instead.
An ACE and ARB should not be combined for treatment.
If hypertension remains uncontrolled with an ACE inhibitor or ARB, offer the choice of a calcium-channel blocker (CCB) or a thiazide-like diuretic.
If hypertension is still not controlled, offer a combination of an ACE inhibitor or ARB, a CCB and a thiazide-like diuretic.
If hypertension is not controlled in adults taking the optimal tolerated doses of an ACE inhibitor or an ARB plus a CCB and a thiazide-like diuretic:
Regard them as having resistant hypertension.
Confirm elevated clinic blood pressure using ambulatory or home blood pressure recordings. Assess for postural hypotension.
For people with confirmed resistant hypertension, consider adding a fourth antihypertensive drug or seeking specialist advice.
Consider further diuretic therapy with low-dose spironolactone if blood potassium level is 4.5 mmol/L or less.
Consider an alpha-blocker or beta-blocker if blood potassium level is more than 4.5 mmol/L.
Si la presión arterial permanece sin control en personas con hipertensión resistente que toman las dosis toleradas óptimas de cuatro medicamentos, consulte a un especialista.
NB: always check safety and appropriate use of each medication for each individual patient - eg, pregnancy, breastfeeding and reduced renal function.13
Actualizaciones exclusivas para profesionales de la salud
Mantente informado con las últimas actualizaciones clínicas, perspectivas profesionales y orientación basada en evidencia. El boletín de Patient Pro selecciona contenido esencial para profesionales de la salud, entregado directamente en tu bandeja de entrada.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.
Lecturas adicionales y referencias
- Diabetes tipo 2 en adultos: manejo; NICE Guidance (December 2015 - last updated February 2026)
- Diabetes - tipo 2; NICE CKS, July 2026 (UK access only)
- Siam NH, Snigdha NN, Tabasumma N, et al; Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies. Rev Cardiovasc Med. 2024 Dec 11;25(12):436. doi: 10.31083/j.rcm2512436. eCollection 2024 Dec.
- Hypertension and diabetes. Part 1: Consequences, definitions, investigations and targets; D Morris; Journal of Diabetes Nursing
- Diabetes and the heart; A J Sullivan et al; Science Direct
- Naseri MW, Esmat HA, Bahee MD; Prevalence of hypertension in Type-2 diabetes mellitus. Ann Med Surg (Lond). 2022 May 14;78:103758. doi: 10.1016/j.amsu.2022.103758. eCollection 2022 Jun.
- Lorber D; Importancia de la gestión del riesgo de enfermedades cardiovasculares en pacientes con diabetes mellitus tipo 2. Diabetes Metab Syndr Obes. 23 de mayo de 2014;7:169-83. doi: 10.2147/DMSO.S61438. eCollection 2014.
- Joshi P, Rick G, Mesineni S, et al; Antihypertensive therapy in diabetes mellitus: efficacy, safety, and metabolic impacts in type 1 and type 2 diabetes. Cardiovasc Diabetol Endocrinol Rep. 2026 Feb 18;12(1):4. doi: 10.1186/s40842-025-00268-y.
- Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease; G Jia and J R Sowers; American Heart Association
- Hipertensión en adultos: diagnóstico y manejo; NICE (August 2019 - last updated February 2026)
- Santulli G; The 2025 AHA/ACC hypertension guidelines: implications for cardiovascular and renal risk in patients with diabetes. Cardiovasc Diabetol Endocrinol Rep. 2025 Aug 26;11(1):21. doi: 10.1186/s40842-025-00239-3.
- Blood Pressure Target in Type 2 Diabetes Mellitus; H-J Kim et al; Diabetes and Metabolism Journal
- Wang S, Djama NM, Lai Y, et al; Cardiovascular outcomes in patients with diabetes when initiating blood pressure lowering at baseline SBP between 130 and 140 mm Hg: A meta-analysis. J Clin Hypertens (Greenwich). 2019 Feb;21(2):220-229. doi: 10.1111/jch.13471. Epub 2019 Jan 13.
- Colosia AD, Palencia R, Khan S; Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013 Sep 17;6:327-38. doi: 10.2147/DMSO.S51325.
- Formulario Nacional Británico (BNF); Servicios de Evidencia NICE (acceso solo en el Reino Unido)
Acerca del revisorVer biografía completa

Dr Toni Hazell, FRCGP
MBBS, BSc, FRCGP, DFSRH, Dip GU med, DRCOG, DCH (London, UK, 2000)
La Dra. Toni Hazell se graduó de la Escuela de Medicina del Hospital St. Mary y realizó su VTS en el Hospital Northwick Park.

Pregunta, comparte, conecta.
Navega por discusiones, haz preguntas y comparte experiencias en cientos de temas de salud.

¿Te sientes mal?
Evalúa tus síntomas en línea de forma gratuita
Más sobre trastornos endocrinos
- Insuficiencia suprarrenal y enfermedad de Addison
- Evaluación del paciente con diabetes establecida
- Hipotiroidismo infantil y congénito
- Cetoacidosis infantil
- Craniofaringiomas
- Pubertad retrasada
- Programas de educación y autogestión de la diabetes
- Diabetes mellitus
- Amiotrofia diabética
- Pie diabético
- Cetoacidosis diabética
- Manejo de emergencia de la hipoglucemia
- Estado hiperglucémico hiperosmolar
- Pubertad normal y anormal
- Síndrome de ovario poliquístico
- Pubertad precoz
- Insuficiencia ovárica prematura
- El paciente con diabetes recién diagnosticada
- Cáncer de tiroides
- Síndrome de Zollinger-Ellison
